AbbVie Shares Dip 1.18% as Stock Slides to 157th in Volume Amid Pricing Scrutiny

Abbvie (ABBV) fell 1.18% on Tuesday, with a trading volume of $0.65 billion, representing a 37.11% decline from the previous day. This marked the stock as the 157th highest volume performer in the market during the session.

Recent developments impacting Abbvie include regulatory scrutiny over its drug pricing practices. The U.S. House Committee on Oversight and Accountability initiated an investigation into the company's pricing strategies for Humira, its flagship rheumatoid arthritis treatment. While no immediate financial penalties or operational disruptions were disclosed, the inquiry has heightened investor concerns about potential legislative reforms in pharmaceutical pricing.

Analysts noted that the stock's underperformance aligns with broader sector trends. Biopharmaceutical stocks faced pressure following a Federal Trade Commission statement warning against "anti-competitive pricing practices." Abbvie's reliance on Humira, which generates over 30% of its revenue, remains a focal point amid ongoing patent litigation and biosimilar competition. However, the company's robust R&D pipeline, including late-stage trials for oncology therapies, continues to anchor long-term investor sentiment.

To run this strategy rigorously I need a bit more detail so I can build the correct data-gathering and back-testing pipeline for you: 1. Market universe • Should we limit the universe to U.S. listed equities (NYSE + NASDAQ) or a different market? • Are ADRs, ETFs, and preferred shares to be included or excluded? 2. Rebalancing logic • Do you want to form the portfolio at each day’s close using that day’s volume ranking, then liquidate at the next day’s close (i.e., a one-day holding period with overnight exposure)? • Equal-weight across the 500 names each day, or weight by something else (e.g., pro-rata volume)? 3. Benchmark / performance metrics • Any particular benchmark you want reported (e.g., S&P 500, equal-weighted universe)? • Beside total return, do you also want drawdown, volatility, Sharpe, etc.? Once I have these points, I can lay out the data-retrieval plan and run the back-test for the 2022-01-03 through today window.